FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies, RPCI-Led Study Shows

Press Release April 3, 2012, CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Disrupts FAK-VEGFR3 Interaction and Inhibits Pancreatic Tumor Growth

Press Release November 14, 2011, CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4

Press Release November 14, 2011, CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Y15

Press Release October 19, 2011, CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum

Life Science Leader magazine, August 2011

Press Release June 22, 2011, CureFAKtor Europe Gastro Congress CFAK-C4 News Release

Press Release April 19, 2011, Developing FAK Inhibitors to Treat Cancer, University of Florida Innovation Showcase 2011

OncLive TechSector Q&A, March 29th, 2011, Article arranged with Dr. Cance on CureFAKtor

 

CBS Radio Network, WCBS-AM.com and Roswell Park Cancer Institute news stories:

January 29, 2012 - Cancer Drug Development with Drs. A. Adjei and W. Cance (Roswell Park podcast)

February 11, 2011 - Working to Cure Cancer (podcast)

February 10, 2011 - CureFAKtor and Cancer (podcast)

February 10, 2011 - Dr. William Cance (podcast)

 

 Buffalo Business First, January 21, 2011 CureFAKtor Cancer Drug Development in Western New York

 

ORPHAN DRUG DESIGNATION - JANUARY 2011

Press Release January 18, 2011, CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer

Oncology Times, Orphan Drug Designation for CFAK-C4 for Treatment of Pancreatic Cancer

Buffalo Business First, FDA Advances RPCI Spinoff's Research

Pharmaceutical Business Review, CureFAKtor Pharma pancreatic cancer treatment gets Orphan drug status

OncoZine, Orphan Drug Designation for FAK Inhibitor in Treatment of Pancreatic Cancer

ASCO Gastrointestinal Cancers Symposium 2011

Press Release January 21, 2011, CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth